Nasal spray could zap COVID-19 virus in the nose
NCT ID NCT05799521
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a nasal spray called Optate in 24 adults with mild COVID-19. The spray aims to lower virus levels in the nose and improve symptoms like congestion. Participants receive either Optate or a placebo, and researchers measure changes in virus levels and symptom scores one hour and 24 hours after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Optate (glycine and alkaline buffer) nasal spray
- What this could lead to
- If it works, this could provide a simple, at-home nasal spray to lower virus levels and ease symptoms for people with mild COVID-19.
- What could go wrong
- This is a small, early-phase trial with only 24 participants, so results may not apply broadly. The treatment is tested only for mild cases and may not work for severe illness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Riley Hospital for Children
Indianapolis, Indiana, 46202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief